Protide Dry Powder Inhalation Capsule (DPI) Inhalation Capsule 50 mcg+100 mcg is a Product of the Generic Salmeterol + Fluticasone Propionate

What Is Protide Dry Powder Inhalation Capsule (DPI) Inhalation Capsule 50 mcg+100 mcg Indications and Uses?

Protide is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate: Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

Pharmacology (Source, Chemical and Physical Composition) Of Protide Dry Powder Inhalation Capsule (DPI) Inhalation Capsule 50 mcg+100 mcg

Protide Dry Powder Inhalation Capsule (DPI) Inhalation Capsule 50 mcg+100 mcg (Salmeterol + Fluticasone Propionate) Xinafoate is a selective, long-acting beta-2 agonist used in the treatment of asthma and other forms of diffuse airway obstruction. Fluticasone Propionate is a corticosteroid with mainly glucocorticoid activity. Fluticasone Propionate is stated to exert a topical effect on the lungs without systematic effects at usual dose. Salmeterol protects against symptoms, Fluticasone Propionate improves lung function and prevents exacerbations of the condition. This preparation can offer a more convenient regime for patients on concurrent β-agonist and inhaled corticosteroid therapy. The respective mechanisms of action of both drugs are discussed below: Salmeterol : Salmeterol is a selective long-acting (12-hour) beta-2-adrenoceptor agonist with a long side chain that binds to the exo-site of the receptor. Fluticasone Propionate : Fluticasone Propionate given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in reduced symptoms and exacerbations of asthma, without the adverse effects observed when corticosteroids are administered systemically.

Drug Interactions of Protide Dry Powder Inhalation Capsule (DPI) Inhalation Capsule 50 mcg+100 mcg

Both non-selective and selective β-blockers should be avoided in patients with asthma, unless there are compelling reasons for their use. Due to the very low plasma concentrations achieved after inhaled dosing clinically significant drug interactions are unlikely. Care should be taken when co-administering known strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir), as there is potential for increased systemic exposure to Fluticasone Propionate.

Side Effects of Protide Dry Powder Inhalation Capsule (DPI) Inhalation Capsule 50 mcg+100 mcg

As Protide contains Protide Dry Powder Inhalation Capsule (DPI) Inhalation Capsule 50 mcg+100 mcg (Salmeterol + Fluticasone Propionate) and Fluticasone Propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. There is no incidence of additional adverse events following concurrent administration of the two compounds. Adverse events, which have been associated with Salmeterol or Fluticasone Propionate, are given below. Salmeterol : The pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. Cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. There have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. There have been reports of oropharyngeal irritation. There have been rare reports of muscle cramps. Fluticasone propionate : Hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. Cutaneous hypersensitivity reactions have been reported. Rare cases of facial and oropharyngeal oedema have been reported. Both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of Salmeterol/ Fluticasone Propionate Inhaler.

Precautions And Warnings for Protide Dry Powder Inhalation Capsule (DPI) Inhalation Capsule 50 mcg+100 mcg

Use in asthma patients : This inhalation capsule should not be initiated in patients during an exacerbation, or if they have unstable or acutely deteriorating asthma. This inhalation capsule is not for relief of acute symptoms for which a fast and short-acting bronchodilator (e.g. salbutamol) is required. Patients should be advised to have their relief medication available at all times. Asthma-related adverse events : Serious asthma-related adverse events and exacerbations may occur during treatment with this inhalation capsule. Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation of this inhalation capsule. Paradoxical Bronchospasm : As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with a fast and short-acting inhaled bronchodilator. This inhalation capsule should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary. The pharmacological side-effects of beta-2 agonist treatment, such as tremor, subjective palpitations and headache have been reported, but tend to be transient and to reduce with regular therapy. Use in COPD patients : There was an increased reporting of pneumonia in studies of patients with COPD receiving Protide Dry Powder Inhalation Capsule (DPI) Inhalation Capsule 50 mcg+100 mcg (Salmeterol + Fluticasone Propionate)/fluticasone inhaler. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbation frequently overlap. Corticosteroids : This inhalation capsule contains an inhaled corticosteroid (fluticasone propionate). Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods; these effects are much less likely to occur than with oral. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation and (very rarely) behavioral disturbances in children and adolescents, decrease in bone mineral density, cataract and glaucoma. Therefore, it is important, that the patient is reviewed regularly and the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control is maintained.

Use During Pregnancy and Lactation

Pregnancy : Administration of this inhalation capsule during pregnancy and lactation should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus or child. There is insufficient experience of the use of Protide Dry Powder Inhalation Capsule (DPI) Inhalation Capsule 50 mcg+100 mcg (Salmeterol + Fluticasone Propionate) xinafoate and fluticasone propionate in human pregnancy. Reproductive toxicity studies in animals, either with single agent or in combination, revealed the fetal effects expected at excessive systemic exposure levels of a potent beta-2- adrenoreceptor agonist & glucocorticosteroid. Lactation : Administration of this inhalation capsule in breast-feeding mothers should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus or child. There is insufficient experience of the use of salmeterol xinafoate and fluticasone propionate in human lactation. Salmeterol and fluticasone propionate concentrations in plasma after inhaled therapeutic doses are very low and therefore concentrations in human breast milk are likely to be correspondingly low. This is supported by studies in lactating animals, in which low concentrations were measured in milk. There are no data available for human breast milk.

Therapeutic Class

Long-acting selective β-adrenoceptor stimulants, Respiratory corticosteroids

Storage Conditions of It

Pressurised canister, do not puncture, break or incinerate even when apparently empty. Avoid storage in direct sunlight or heat. Store below 30°C. Keep away from eyes. Keep away from children. Pack Image: Protide 50 mcg+100 mcg Inhalation Capsule Thanks for using MedEx! How would you rate your experience so far?